Greaves M & Maley CC (2012) Clonal evolution in cancer. Nature 481, 306–313.
Junttila MR & Evan GI (2009) p53—a Jack of all trades but master of none. Nat. Rev. Cancer 9, 821–829.
Levine AJ (2009) The common mechanisms of transformation by the small DNA tumor viruses: the inactivation of tumor suppressor gene products: p53. Virology 384, 285–293.
Lu P, Weaver VM & Werb Z (2012) The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 196, 395–406.
Mitelman F, Johansson B & Mertens F (2007) The impact of translocations and gene fusions on cancer causation. Nat. Rev. Cancer 7, 233–245.
Negrini S, Gorgoulis VG & halazonetis TD (2010) Genomic instability— an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 11, 220–228.
Nguyen DX, Bos PD & Massagué J (2009) Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer 9, 274–284.
Radtke F & Clevers h (2005) Self-renewal and cancer of the gut: two sides of a coin. Science 307, 1904–1909.
Rowley JD (2001) Chromosome translocations: dangerous liaisons revisited. Nat. Rev. Cancer 1, 245–250.
Shaw RJ & Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441, 424–430.
Suvà ML, Riggi N & Bernstein BE (2013) Epigenetic reprogramming in cancer. Science 339, 1567–1570.
Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81, 323–330.
Cancer Prevention and Treatment: Present and Future
Al-hajj M, Becker MW, Wicha M et al. (2004) Therapeutic implications of cancer stem cells. Curr. Opin. Genet. Dev. 14, 43–47.
Ames B, Durston WE, Yamasaki E & Lee FD (1973) Carcinogens are mutagens: a simple test system combining liver homogenates for activation and bacteria for detection. Proc. Natl Acad. Sci. USA 70, 2281–2285.
Bozic I, Reiter JG, Allen B et al. (2013) Evolutionary dynamics of cancer in response to targeted combination therapy. eLife 2, e00747.
Doll R & Peto R (1981) The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J. Natl Cancer Inst. 66, 1191–1308.
Druker BJ & Lydon NB (2000) Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. 105, 3–7.
huang P & Oliff A (2001) Signaling pathways in apoptosis as potential targets for cancer therapy. Trends Cell Biol. 11, 343–348.
Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58–62.